After long-term ADT … recovery of normal hormonal function?

A group of Spanish clinical researchers have reported recent data from a small study designed to address an unanswered question about the recovery of (relatively) normal hormonal function after completion of androgen deprivation therapy (ADT). … READ MORE …

ADT and the risk for depression

It will come as no great surprise to most readers of this blog that androgen deprivation therapy (ADT) used in the treatment of  men with progressive forms of prostate cancer comes with a significant risk for depression (as well as other effects on cognitive function). … READ MORE …

The risk for cardiovascular events among prostate cancer patients on ADT (again)

As our regular readers will be well aware, the topic of risk for cardiovascular disease among prostate cancer patients being treated with any form of androgen deprivation therapy (ADT, also known as “hormone” therapy) comes up on a regular basis. … READ MORE …

ADT, patient survival, and serum testosterone levels after initiation of treatment

Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Hormonal therapy and risk for blood clots for men on ADT

An article just published in the journal Cancer has reported an association between the use of androgen deprivation therapy (ADT) and risk for blood clots among men being treated for prostate cancer. … READ MORE …

Can CTC levels predict progression of hormone-sensitive prostate cancer?

The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with  metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents. … READ MORE …